27 research outputs found

    Risk of breast cancer death by current pre-diagnostic and post-diagnostic statin use within a cohort of all breast cancer patients diagnosed in Finland during 1995–2003.

    No full text
    <p>Analysis stratified by propensity for post-diagnostic statin use, population characteristics at baseline and primary treatment selection.</p>a<p>Calculated with Cox regression model adjusted for age, tumor stage and morphology and treatment selection.</p>b<p>Propensity for post-diagnostic statin usage as a function of age, tumor stage and morphology, initial treatment choice and pre-diagnostic statin use.</p><p>Risk of breast cancer death by current pre-diagnostic and post-diagnostic statin use within a cohort of all breast cancer patients diagnosed in Finland during 1995–2003.</p

    Risk of breast cancer death by amount, years and intensity of post-diagnostic statin use as compared to non-users.

    No full text
    <p>Statin users limited to new post-diagnostic users only.</p>a<p>Calculated with Cox regression model adjusted for age, tumor stage and morphology and treatment selection.</p><p>DDD = Defined Daily Dose.</p><p>Risk of breast cancer death by amount, years and intensity of post-diagnostic statin use as compared to non-users.</p

    Risk of breast cancer death by amount, duration and intensity of post-diagnostic statin use compared to non-users in a cohort of all breast cancer cases diagnosed in Finland during 1995–2003.

    No full text
    a<p>Calculated with Cox regression model adjusted for age, tumor stage and morphology, treatment selection and pre-diagnostic statin use.</p><p>DDD = Defined Daily Dose.</p><p>Risk of breast cancer death by amount, duration and intensity of post-diagnostic statin use compared to non-users in a cohort of all breast cancer cases diagnosed in Finland during 1995–2003.</p

    Breast cancer-specific and overall mortality by current pre-diagnostic and post-diagnostic use of specific statins.

    No full text
    <p>Cohort of all breast cancer patients diagnosed in Finland during 1995–2003.</p><p>*Statin types are not mutually exclusive, i.e. person who has used two types of statins (e.g. atorvastatin and simvastatin) is counted as a user in both categories.</p>†<p>Calculated with Cox regression model adjusted for age, tumor stage and morphology, treatment selection and pre-diagnostic statin use.</p><p>Breast cancer-specific and overall mortality by current pre-diagnostic and post-diagnostic use of specific statins.</p

    Baseline population characteristics of all breast cancer cases diagnosed in Finland during 1995–2003.

    No full text
    a<p>Any pre-diagnostic or post-diagnostic use.</p>b<p>Age cutoffs selected to reflect menopausal status of the majority of women at breast cancer diagnosis.</p><p>Baseline population characteristics of all breast cancer cases diagnosed in Finland during 1995–2003.</p

    Trend in breast cancer mortality by intensity (doses/year) of pre-diagnostic statin use.

    No full text
    <p>Nationwide cohort of all female breast cancer patients in Finland during 1995–2003.</p

    Overall risk of death among post-diagnostic and pre-diagnostic statin users compared to non-users.

    No full text
    <p>Cohort of all breast cancer patients diagnosed in Finland during 1995–2003.</p><p>*Calculated with Cox regression model adjusted for age, tumor stage and morphology and treatment selection.</p><p>DDD = Defined Daily Dose.</p><p>Overall risk of death among post-diagnostic and pre-diagnostic statin users compared to non-users.</p

    Do Breast Cancer Cell Lines Provide a Relevant Model of the Patient Tumor Methylome?

    No full text
    <div><p>It is well documented that tumor cells undergo dramatic genetic and epigenetic changes during initial establishment as cell lines and in subsequent serial passaging, and that the resultant cell lines may have evolved significantly from the primary tumors from which they were derived. This has potential implications due to their widespread use in drug response experiments and studies of genomic function. One approach to optimizing the design of such cell line studies is to identify and use the cell lines that faithfully recapitulate critical features of primary tumors. To evaluate the epigenetic fidelity of breast cancer cell lines in the context of primary tumors, we performed methylation profiling of 55 well-characterized breast cancer cell lines on the Illumina HumanMethylation27 BeadChip platform, and compared them to publicly available methylation profiles of primary breast tumors. We found that the DNA methylation profiles of breast cancer cell lines largely retain the features that characterize primary tumors, although there are crucial differences as well. We describe these similarities and differences between primary tumors and breast cancer cell lines in detail, and develop a quantitative measure of similarity that is used to score each cell line with respect to how faithfully its methylation profile mirrors that of primary tumors.</p></div

    Gene expression profiles of luminal-like triple negative cell lines are least like primary tumors as well.

    No full text
    <p>Comparison of each individual cell line expression profiles to their closest primary tumor match supports the finding from our analysis of methylation profiles that B-CIMP+, triple-negative breast cancer cell lines are among the least likely to have a close match. <u>Panel A</u>: The x-axis of each plot indexes cell lines, arranged by phenotypic status, and the y-axis shows the Spearman Correlation Distance to the nearest primary tumor by expression profile. In the top half of the figure, the comparison is made to Sotiriou samples <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0105545#pone.0105545-Farmer1" target="_blank">[23]</a>, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0105545#pone.0105545-Sotiriou1" target="_blank">[24]</a>, while in the bottom half, the comparison is made to the Farmer validation dataset <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0105545#pone.0105545-Farmer1" target="_blank">[23]</a>, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0105545#pone.0105545-Sotiriou1" target="_blank">[24]</a>. The median distance for all 50 cell lines is shown as a horizontal line as a reference point, and the color of adjacent points alternates to aid in tracking results across the two plots. <u>Panel B</u>: Boxplots in show the distribution of best-match distances, broken down by major phenotypic combinations as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0105545#pone-0105545-g003" target="_blank">Figure 3</a>.</p
    corecore